College of Nursing Art and Science (J.K.), University of Hyogo, Akashi, Japan.
Faculty of Nursing, National Defense Medical College (M.K.), Tokorozawa, Japan.
J Pain Symptom Manage. 2022 Aug;64(2):e83-e89. doi: 10.1016/j.jpainsymman.2022.04.171. Epub 2022 Apr 19.
The Dyspnea-12 questionnaire is a simple tool to assess dyspnea using qualitative descriptors that include both physical and emotional domains. However, the reliability and validity of the Japanese version in patients with lung cancer have not been assessed.
To determine the reliability and validity of the Japanese version of the Dyspnea-12 questionnaire in patients with lung cancer.
The assessment was based on the numerical rating scale (NRS), cancer dyspnea scale (CDS), and hospital anxiety and depression scale (HADS). Spearman's correlation assessed the convergent validity of Dyspnea-12 using these three scales. Exploratory factor analysis examined the construct validity. The reliability was verified using Cronbach's alpha. Anxiety, depression, clinical dyspnea, presence of chronic obstructive pulmonary disease (COPD), and patient status were identified by discriminating performance.
The analysis included 113 patients with lung cancer. A significant positive correlation was found between Dyspnea-12 and NRS, CDS, and HADS scores. Similar to the original version, factor analysis clearly classified Dyspnea-12 into two components (physical and emotional), thereby confirming its construct validity. Cronbach's alpha values for the total Dyspnea-12 and its physical and emotional components were 0.97, 0.95, and 0.96, respectively. Patients with anxiety, depression, and clinical dyspnea and those in the palliative phase had significantly higher Dyspnea-12 scores than their respective counterparts. The Dyspnea-12 scores of patients with and without COPD were similar.
The Japanese version of the Dyspnea-12 questionnaire is a useful and reliable tool to assess the multi-dimensional aspects of dyspnea in patients with lung cancer.
呼吸困难-12 问卷是一种简单的工具，用于使用包括身体和情绪领域的定性描述符评估呼吸困难。然而，尚未评估其在肺癌患者中的可靠性和有效性。
确定肺癌患者呼吸困难-12 问卷的日语版本的可靠性和有效性。
评估基于数字评分量表（NRS）、癌症呼吸困难量表（CDS）和医院焦虑和抑郁量表（HADS）。Spearman 相关分析使用这三个量表评估 Dyspnea-12 的收敛效度。探索性因素分析检查了结构效度。使用 Cronbach 的 alpha 验证了可靠性。通过判别性能确定焦虑、抑郁、临床呼吸困难、慢性阻塞性肺疾病（COPD）的存在和患者状况。
分析包括 113 例肺癌患者。Dyspnea-12 与 NRS、CDS 和 HADS 评分之间存在显著正相关。与原始版本类似，因子分析清楚地将 Dyspnea-12 分为两个分量（身体和情绪），从而确认了其结构有效性。Dyspnea-12 总分及其身体和情绪分量的 Cronbach 的 alpha 值分别为 0.97、0.95 和 0.96。有焦虑、抑郁和临床呼吸困难以及处于姑息治疗阶段的患者的 Dyspnea-12 评分明显高于相应患者。有和没有 COPD 的患者的 Dyspnea-12 评分相似。
呼吸困难-12 问卷的日语版本是一种有用且可靠的工具，可用于评估肺癌患者呼吸困难的多维方面。
